ArticleEndocrine2012
Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.
Article in Endocrine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Article
- The tissue distribution of nucleobindin-2/nesfatin-1 in the reproductive organs of bitches with regard to the animal's age and body weight.Journal of veterinary research · 2025Article
- Article
- Article
- Increased Serum Levels of Phoenixin-14, Nesfatin-1 and Dopamine Are Associated with Positive Pregnancy Rate after Ovarian Stimulation.Journal of clinical medicine · 2023Article
- Circulating nesfatin-1 levels in women with polycystic ovary syndrome: A systematic review and meta-analysis.International journal of reproductive biomedicine · 2023Review
- Review of Novel Potential Insulin Resistance Biomarkers in PCOS Patients-The Debate Is Still Open.International journal of environmental research and public health · 2022Review
- Anorexigenic peptide (leptin, obestatin, nesfatin-1) levels and their impact on assisted reproductive technology treatment outcomes in patients with polycystic ovary syndrome.Clinical and experimental reproductive medicine · 2021Article
- DLK1 and Nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled studyTurkish journal of obstetrics and gynecology · 2021Article
- The Oral Glucose Tolerance Test-Is It Time for a Change?-A Literature Review with an Emphasis on Pregnancy.Journal of clinical medicine · 2020Review
- Serum nesfatin-1 and galanin concentrations in the adult with metabolic syndrome. Relationships to insulin resistance and obesity.Saudi medical journal · 2019Article
- The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction.Acta Cardiologica Sinica · 2018Article
- Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.Endocrine · 2016Review
- Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome.Sleep & breathing = Schlaf & Atmung · 2015Article
- Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Assessment of FSHR, AMH, and AMHRII variants in women with polycystic ovary syndrome.Endocrine · 2015Article
- Gastrointestinal hormones and polycystic ovary syndrome.Endocrine · 2014Review
- Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome.Journal of endocrinological investigation · 2014Article
- Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.Endocrine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is commonly characterised by obesity, insulin resistance (IR), hyperandrogenemia and hirsutism. Nesfatin-1 a recently discovered hormone, acts upon energy balance, glucose metabolism, obesity and probably gonadal functions. This study was to evaluate the circulating levels of nesfatin-1 in patients with PCOS (n = 30) and in age and body mass index (BMI)-matched controls (n = 30). PCOS patients had significantly lower levels of nesfatin-1 (0.88 ± 0.36 ng/mL) than healthy controls (2.22 ± 1.14 ng/mL). PCOS patients also had higher gonadotropin and androgen plasma concentrations, Ferriman-Gallwey scores, blood glucose levels and a homeostasis model of assessment-IR index (HOMA-IR) index than in healthy women. Correlation tests in PCOS subjects detected a negative correlation between nesfatin-1 levels and BMI, fasting blood glucose, insulin levels and a HOMA-IR index. Lower nesfatin-1 concentration may plays a very important role in the development of PCOS.
Indexed as
Identifiers
22367584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.